AngioDynamics, Inc. (ANGO) Dividend History

Company News

• 3 Stocks Insiders Are Buying Heavily in October and Why

  Insiders have been making significant purchases in Eton Pharmaceuticals, AngioDynamics, and Tile Shop Holdings, indicating their confidence in these companies' prospects.

  Investing.com
• AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  AngioDynamics (ANGO) has seen a 15.9% decline in the past four weeks, but its oversold RSI and improved earnings estimates suggest a potential turnaround may be on the horizon.

  Benzinga
• Why AngioDynamics Stock Is Crashing Today

  AngioDynamics, a medical technology company, reported mixed results for its fiscal Q1, with revenue slightly missing estimates but adjusted loss per share better than expected. The company maintained its full-year guidance, but its growth prospects are not seen as exciting compared to other stocks.

  The Motley Fool
• AngioDynamics stock target raised on growth prospects - Investing.com

  Oppenheimer raised its price target for AngioDynamics stock to $13 from $12, citing the company's strong fourth-quarter sales, particularly in its higher-margin and growth segments. The firm also noted AngioDynamics' efforts to expand EBITDA and reach profitability by fiscal year 2027.

  Investing.com

  Featured Companies: MMSI
• U.S. Autoimmune Disease Diagnostics (Systemic, Localized) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire

  The U.S. autoimmune disease diagnostics market is expected to reach $3.01 billion by 2030, driven by the rising incidence of autoimmune diseases and advancements in diagnostic technologies. Localized autoimmune disease diagnostics and antinuclear antibody tests are expected to dominate the market.

  GlobeNewswire Inc.

  Featured Companies: BSX BVS JNJ MDT